Arcutis Biotherapeutics (ARQT) Depreciation & Amortization (CF) (2019 - 2025)
Arcutis Biotherapeutics (ARQT) posted quarterly Depreciation & Amortization (CF) of $153000.0 for Q1 2025, down 10.0% year-over-year from $170000.0 in Q1 2024, and up 45.71% quarter-over-quarter from $105000.0 in Q4 2024.
Arcutis Biotherapeutics (ARQT) Depreciation & Amortization (CF) (2019 - 2025) Analysis & Trends
Arcutis Biotherapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $153000.0 for Q1 2025.
- In Q1 2025, Depreciation & Amortization (CF) fell 10.0% year-over-year to $153000.0; the TTM figure through Dec 2025 stood at $153000.0 (down 74.5% YoY), while the FY2024 annual figure was $600000.0, down 25.0% from the prior year.
- Depreciation & Amortization (CF) for Q1 2025 stood at $153000.0, up from $105000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $227000.0 in Q4 2023, with the low at $98000.0 in Q1 2021.
- The 5-year median for Depreciation & Amortization (CF) is $160000.0 (2022), against an average of $157352.9.
- The sharpest annual moves came in 2021 and 2024: Depreciation & Amortization (CF) jumped 1300.0% in 2021, then tumbled 53.74% in 2024.
- Arcutis Biotherapeutics' Depreciation & Amortization (CF) stood at $182000.0 in 2021, then decreased by 12.09% to $160000.0 in 2022, then surged by 41.88% to $227000.0 in 2023, then sank by 53.74% to $105000.0 in 2024, then surged by 45.71% to $153000.0 in 2025.
- Business Quant data shows ARQT's Depreciation & Amortization (CF) at $153000.0 in Q1 2025, $105000.0 in Q4 2024, and $161000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 153,000.00 |
| Mar 31, 2025 | 153,000.00 |
| Dec 31, 2024 | 105,000.00 |
| Dec 31, 2024 | 105,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 164,000.00 |
| Jun 30, 2024 | 164,000.00 |
| Mar 31, 2024 | 170,000.00 |
| Mar 31, 2024 | 170,000.00 |
| Dec 31, 2023 | 227,000.00 |
| Dec 31, 2023 | 227,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 198,000.00 |
| Jun 30, 2023 | 198,000.00 |
| Mar 31, 2023 | 175,000.00 |
| Mar 31, 2023 | 175,000.00 |
| Dec 31, 2022 | 160,000.00 |
| Dec 31, 2022 | 160,000.00 |